Global Stem Cells Group has Announced an Agreement with Rokit Healthcare
Global Stem Cells Group has hereby announced an agreement with the biotechnology company known as Rokit Healthcare to promote and distribute the Invivo to the people of Latin America and surrounding areas, for regenerative medicine applications worldwide and the furtherance of the field.
The Global Stem Cells Group (GSCG) is a company that seeks to become the world leader in adult stem cell therapies and physician training in stem cell protocols and medical procedures. To achieve this goal, they provide superior regenerative medicine products, supplies, and experience to the medical community. Because of this, GSCG has signed an agreement with South Korean-based Rokit Healthcare, which is a bioprinter manufacturer that is committed to advance the field of regenerative medicine and, as a result, better the quality of life of people around the world.
About Rokit Healthcare
The field of bioprinting is an extremely new one, but it shows great promise. Simply, it is the automated, computer aided deposition of bio-materials (which are cells, stem cell growth factors, and biocompatible polymers) for the manufacturing of functional human tissues or organs. Stem cells, or other growth factors, are harvested and used with a proprietary printing technology to create or regenerative damaged or diseased organs. Rokit Healthcare does this primarily through the proliferation of a machine that they dub an ‘organ regenerator’– it looks like a 3D printer, but instead of using plastics to create things, they use cells and materials that will be safe to implant within the human body.
3D bioprinting of human tissues and organs is a revolutionary technology in the field of tissue engineering. One of the major challenges in stem cell research and tissue engineering is mimicking the micro and macro environment of human tissues. A favorable functional outcome is extremely dependent on the level to which tissue scientist and engineers are able to control the inner micro- and macro-scale features of engineered-tissue. In response to this challenge, advances in additive manufacturing inspired scientists to develop and adapt 3D bioprinting technology for human tissues and organs.
With the advancements of 3D printing and regenerative medicine working together, the potential is seemingly limitless for the spreading of bioprinting technology, a process that is known as 4D Printing– and Global Stem Cells Group, in an effort to bring this revolutionary technology to the forefront of people’s minds around the world, has forged an agreement with Rokit Healthcare to obtain the exclusive rights to brand, promote, and distribute the product within Latin America– Of course, with the global network of GSCG, the machine will be available elsewhere in the world, but the Group will focus their efforts on Latin America.
The Invivo 3D Printer is their product, and they have been working since 2012 in the field of regenerative medicine. The result of eight years of research and development, their newest model revolutionizes the application of stem cells and growth factors– by creating a solution for personalized and improved patient care. By leveraging 3D bioprinting technology, it can better distribute a patient’s autologous tissues and cells, making it an invaluable tool for those that are looking to improve the efficacy of their results, especially for certain dermatological conditions including scarring.
Adimarket, Inc., a division of the Global Stem Cells Group, is a one-stop, cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals. Adimarket was founded to provide practitioners the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting-edge treatments.
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.